Englander Institute for Precision Medicine

Lineage Reversion Drives WNT Independence in Intestinal Cancer.

TitleLineage Reversion Drives WNT Independence in Intestinal Cancer.
Publication TypeJournal Article
Year of Publication2020
AuthorsHan T, Goswami S, Hu Y, Tang F, Zafra MPaz, Murphy C, Cao Z, Poirier JT, Khurana E, Elemento O, Hechtman JF, Ganesh K, Yaeger R, Dow LE
JournalCancer Discov
Volume10
Issue10
Pagination1590-1609
Date Published2020 Oct
ISSN2159-8290
KeywordsAnimals, Cell Line, Tumor, Humans, Intestinal Neoplasms, Mice, Wnt Signaling Pathway
Abstract

The WNT pathway is a fundamental regulator of intestinal homeostasis, and hyperactivation of WNT signaling is the major oncogenic driver in colorectal cancer. To date, there are no described mechanisms that bypass WNT dependence in intestinal tumors. Here, we show that although WNT suppression blocks tumor growth in most organoid and colorectal cancer models, the accumulation of colorectal cancer-associated genetic alterations enables drug resistance and WNT-independent growth. In intestinal epithelial cells harboring mutations in or , together with disruption of and , transient TGFβ exposure drives YAP/TAZ-dependent transcriptional reprogramming and lineage reversion. Acquisition of embryonic intestinal identity is accompanied by a permanent loss of adult intestinal lineages, and long-term WNT-independent growth. This work identifies genetic and microenvironmental factors that drive WNT inhibitor resistance, defines a new mechanism for WNT-independent colorectal cancer growth, and reveals how integration of associated genetic alterations and extracellular signals can overcome lineage-dependent oncogenic programs. SIGNIFICANCE: Colorectal and intestinal cancers are driven by mutations in the WNT pathway, and drugs aimed at suppressing WNT signaling are in active clinical development. Our study identifies a mechanism of acquired resistance to WNT inhibition and highlights a potential strategy to target those drug-resistant cells..

DOI10.1158/2159-8290.CD-19-1536
Alternate JournalCancer Discov
PubMed ID32546576
PubMed Central IDPMC7541594
Grant ListK08 CA230213 / CA / NCI NIH HHS / United States
P30 CA008748 / CA / NCI NIH HHS / United States
R01 CA222517 / CA / NCI NIH HHS / United States
T32 CA203702 / CA / NCI NIH HHS / United States

Weill Cornell Medicine Englander Institute for Precision Medicine 413 E 69th Street
Belfer Research Building
New York, NY 10021